Want to see SERA full AI Analyst Report?
EarningsQ2 2026 Earnings Report
SERA Q2 2026 EPS Results
Actual EPS-$0.18
Consensus EPS-$0.15
Beat/MissMissed by -$0.03
One Year Ago EPS-$0.16
SERA Q2 2026 Revenue Results
Actual Revenue$30.00K
Expected Revenue$71.00K
Beat/MissMissed by -$41.00K
YoY Revenue Growth+76.47%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeAfter Close
Conference CallWednesday, August 12, 2026
SERA Upcoming Earnings
Sera Prognostics's next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
SERA Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple strategic, clinical and policy wins—most notably the PRIME subgroup results, Illinois Medicaid coverage, expanded payer engagement (>20 payer opportunities) and a strengthened evidence and European regulatory pathway—while acknowledging that commercial revenue remains nascent, operating losses have increased, and meaningful utilization will require multi-step execution across months to years. On balance, achievements around evidence, policy and payer pipeline materially improve the long-term commercialization outlook even as short-term revenue and adoption timelines remain constrained.Company Guidance
PRIME Subgroup Outcomes in First-Time Mothers
Publication of PRIME subgroup analysis showed a 22% reduction in NICU admissions, a twofold reduction (≈50%) among newborns following spontaneous preterm birth, a 30% reduction in severe composite neonatal morbidity, and a number needed to screen and treat (NNT) of 28 to prevent one NICU admission. First-time mothers represent ~40% of U.S. pregnancies, strengthening clinical relevance.
Illinois Medicaid Coverage Milestone
Passage of Illinois legislation requires Medicaid coverage and reimbursement for prescribed proteomic blood tests and associated care management services—expanding access to tens of thousands of Medicaid pregnancies annually and serving as a potential blueprint for other states.
Expanded Payer Engagement Pipeline
Company exceeded its goal of doubling payer discussions (target 15–17 states) and is now engaged with more than 20 payer opportunities across over 20 states, accelerating market access discussions and referrals among payers.
Partnership and Program Growth
Launched the fourth partnership program (state-based initiative with a national payer) and remains on track toward goal of establishing 5–7 commercial programs to support implementation and quality-improvement objectives.
Commercial Traction & Increasing Testing Volume
Revenue rose to $30,000 in Q2 2026 from $17,000 in Q2 2025 (≈+76.5%), and management reported testing volumes increasing steadily month-to-month since PRIME publication, indicating growing provider awareness and engagement.
Stronger Clinical & Economic Evidence Generation
Two PRIME-related abstracts accepted at SMFM (one oral presentation, one top poster) and health economics analysis slated for publication soon, further validating clinical and economic value for payer discussions.
European Regulatory Progress
Published European expert commentary, convened a 9-country European expert advisory board, decided to perform additional ELISA-based performance testing to de-risk CE-mark submission; pre-application activities planned for Q3 and full CE package submission expected in Q4.
Strategic Collaborations and Innovation
Started an ARPA-H-supported multi-institutional collaboration to develop a novel point-of-care diagnostic for fetal hypoxia risk leveraging Sera's biomarker capabilities—validating scientific platform and expanding pipeline partnerships with limited incremental cost.
Awareness and Thought Leadership Initiatives
Scaled digital and social engagement, hosted an on-demand webinar and participated in a Medscape podcast to raise provider and patient awareness—executed with disciplined spending through scalable digital platforms and third-party partnerships.
Balance Sheet and Runway
Ended Q2 2026 with $80.3 million in cash, cash equivalents and available-for-sale securities; management believes this funding is sufficient to support significant adoption and commercial milestones through 2029.
Leadership and Governance Strengthening
Added key commercial leadership (marketing and payer strategy) and appointed Mark Capone to the Board to enhance execution capabilities.
SERA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed